Keratinocyte growth factor in Acute lung injury to REduce pulmonary dysfunction. A randomised placebo controlled trial.
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2016
Price : $35 *
At a glance
- Drugs Palifermin (Primary)
- Indications Acute lung injury
- Focus Therapeutic Use
- Acronyms KARE
- 19 Mar 2014 Planned End Date changed from 31 Dec 2014 to 6 Mar 2014.
- 19 Mar 2014 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network record.